Category: SeaPRwire

SHENZHEN, Jan 24, 2025 – (ACN Newswire) – China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group” or “CMS”) is pleased to announce that on 24 January 2025, the Group through subsidiaries of the Company entered into a Collaboration Agreement with Hunan Mabgeek Biotechnology Co., Ltd. (“Mabgeek Biotechnology”) and its subsidiary for Class 1 innovative drug anti-IL-4Rα humanized monoclonal antibody injection MG-K10 (“MG-K10” or the “Product”). The Group has obtained the co-development right as specifically agreed upon in the Agreement and exclusive commercialization right to the Product in Mainland China, Hong Kong Special Administrative Region, Macao Special Administrative Region, Taiwan Region and Singapore (the “Territory”); Mabgeek Biotechnology will support the commercialization activities and is responsible for the sale and supply of the Product. The collaboration term is perpetual. IL-4Rα is considered a key target for the treatment of type 2 inflammatory diseases, such as atopic dermatitis (AD), asthma, prurigo nodularis, etc. Anti-IL-4Rα monoclonal antibodies are among the best-selling biologics in this field. MG-K10 is an innovative long-acting anti-IL-4Rα humanized monoclonal antibody that simultaneously blocks the signaling of key type 2 inflammatory cytokines IL-4 and IL-13. Following Fc mutation, MG-K10 allows long dosing interval owing to its prolonged half-life, and it is expected to be the first long-acting anti-IL-4Rα monoclonal antibody marketed in China. Currently marketed anti-IL-4Rα drugs require dosing every two weeks, whereas MG-K10 only requires dosing every four weeks, demonstrating good efficacy and safety. MG-K10 has the potential to be the Best-in-Class (BIC). This collaboration marks another significant milestone for Dermavon (formerly known as CMS Skinhealth)’s layout in the dermatology field. MG-K10 will enrich the global differentiated innovative pipeline of Dermavon, and will strongly synergize with the existing product portfolio, such as marketed innovative drug ILUMETRI (tildrakizumab injection), marketed exclusive drug Hirudoid (mucopolysaccharide polysulfate cream) and dermatology-grade skincare products of Heling soothing product series (developed for AD patients), and innovative pipeline drugs ruxolitinib cream (for the topical treatment of mild to moderate AD and non-segmental vitiligo) and povorcitinib (for the treatment of non-segmental vitiligo, hidradenitis suppurativa, prurigo nodularis and chronic spontaneous urticaria), etc. Leveraging its proven clinical development and commercialization capabilities, the Group will fully cooperate with Mabgeek Biotechnology to promote the approval of MG-K10 in China, bringing a new treatment option with lower dosing frequency, good efficacy and safety to patients with type 2 inflammatory diseases in China. More information about MG-K10 MG-K10 is a Class 1 innovative drug anti-IL-4Rα humanized monoclonal antibody injection that used for the treatment of type 2 inflammatory diseases, including AD, asthma, prurigo nodularis, allergic rhinitis, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, chronic obstructive pulmonary disease and so on. It holds substance patents in specific countries/regions within the Territory. MG-K10 has entered Phase III clinical trials in China for AD, asthma, and prurigo nodularis. In the completed Phase II clinical trials for adult moderate-to-severe AD and moderate-to-severe asthma, MG-K10 has demonstrated good efficacy and safety[1-2]. Additionally, MG-K10 has obtained IND approval for eosinophilic esophagitis, chronic rhinosinusitis with nasal polyps, and seasonal allergic rhinitis in China. According to Frost & Sullivan, the global market for treatments targeting IL-4Rα is expected to reach US$28.7 billion by 2030, with a compound annual growth rate (CAGR) of 21.8% from 2020 to 2030. In China, the market is projected to reach US$4.08 billion by 2030, with a CAGR of 76.8% from 2020 to 2030. About AD indication MG-K10’s first indication, AD, is a chronic inflammatory skin condition characterized by severe itching. It is the most burdensome non-fatal skin disease globally, with at least 230 million people affected worldwide[3]. AD is also a prevalent and high-burden chronic disease in China, with the prevalence showing an upward trend[3]. According to the Global Burden of Disease Study 2019, the number of AD patients in China increased by 25.65% from 1990 to 2019[3]. It is estimated that there are approximately 36.09 million AD patients in China[3], with approximately 9.625 million suffering from moderate-to-severe AD[4]. Current treatment options for AD primarily include topical and systemic treatments. For moderate-to-severe AD, topical medications are often insufficient to achieve disease control, necessitating the initiation of systemic treatments. However, due to the limitations in efficacy and safety of traditional systemic therapies for AD, moderate-to-severe AD patients often experience delays in systemic treatment initiation, poor compliance, and suboptimal disease control, leaving a significant unmet need in clinical practice[3]. MG-K10, with its extended dosing interval of once every four weeks, is expected to improve patient adherence and provide a new, effective, and safe systemic treatment option for patients with moderate-to-severe AD. About Mabgeek Biotechnology Mabgeek Biotechnology was founded in 2016 and has always adhered to the research and development concept of “innovation, efficiency and safety”, focusing on the fields of allergic inflammatory diseases and autoimmune diseases. Mabgeek Biotechnology is equipped with a research and development team composed of top industry experts. With excellent research capabilities and deep industry experience, Mabgeek Biotechnology uses its unique TEADA high-throughput antibody screening platform to develop innovative antibody drugs with high biological activity, excellent druggability, and differentiation. Mabgeek Biotechnology is committed to providing safer, more effective and more convenient treatment solutions for patients worldwide. For more information about Mabgeek Biotechnology and its products, please visit: https://www.mabge.com/. About CMS CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs. CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients. CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development of its advantageous specialty fields and expand business boundaries. While strengthening the competitiveness of the cardio-cerebrovascular/gastroenterology business, CMS independently operates its dermatology and medical aesthetics business, and ophthalmology business, aiming to gain leading positions in specialty therapeutic fields, whilst enhancing the scale and efficiency. At the same time, CMS has expanded its business territory to the Southeast Asian market, striving to become a “bridgehead” for global pharmaceutical companies to enter the Southeast Asian market, further escorting the sustainable and healthy development of the Group. Reference: The data of the product’s Phase II clinical trial for AD indication as disclosed by Mabgeek: https://www.mabge.com/en/index.php?c=show&id=23 The interim data of the product’s Phase II clinical trial for asthma indication as disclosed by Mabgeek: https://www.mabge.com/index.php?c=show&id=18 Chinese Society of Dermatology, China Dermatologist Association. Clinical pathway for the diagnosis and treatment of moderate to severe atopic dermatitis in China (2023): an expert consensus[J]. Chinese Journal of Dermatology, 2023, 56(11): 1000-1007. DOI: 10.35541/cjd.20230247. Mao, Dandan et al. Prevalence and risk factors of atopic dermatitis in Chinese adults: a nationwide population-based cross-sectional study. Chinese medical journal vol. 136,5 604-606. 5 Mar. 2023, DOI:10.1097/CM9.0000000000002560 CMS Disclaimer and Forward-Looking Statements This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert. This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections. Media Contact Brand: China Medical System Holdings Ltd. Contact: CMS Investor Relations Email: ir@cms.net.cn Website: https://web.cms.net.cn/en/home/ Source: China Medical System Holdings Ltd.

New York, NY - January 20, 2025 - As the cryptocurrency world continues to evolve, a new project has emerged that combines artificial intelligence with the iconic brand of Donald Trump: AI Trump Coin ($AITRUMP). Unlike the previously launched Trump Coin ($TRUMP), which garnered significant attention, AI Trump Coin aims to bring a unique blend of AI technology to the crypto market. Presale Launch and Pricing The $AITRUMP presale is now live, offering participants the opportunity to acquire tokens at an early stage. In this initial phase, 1 $AITRUMP is priced at $0.00025. Payments can be made using ETH, SOL, BNB, USDC, and USDT. As the presale progresses, the price will increase incrementally by 5% at each stage, encouraging early adoption. Transparency and Project Details AI Trump Coin is built on the Solana blockchain and seeks to differentiate itself with a focus on AI-driven utilities. Here are some key aspects of the project: AI Trump Digital Twin: AI Trump is an artificial intelligence-based digital representation of Donald Trump, designed to engage with users across social media platforms such as X, Instagram, Facebook, and Truth Social. This feature aims to provide interactive experiences that emulate Trump's communication style. Exclusive Utilities for Token Holders: $AITRUMP holders will gain access to a range of exclusive utilities, including AI-driven social media sponsorships and consulting services. These utilities are designed to offer value beyond typical meme coin functionalities. Roadmap and Future Developments: The project roadmap includes launching AI Trump on multiple social media platforms, developing AI-driven campaigns, integrating NFTs, and expanding its ecosystem with further technological advancements. Tokenomics Overview Total Supply: 100 billion tokens Allocation: - AI Development: 20% - Marketing: 20% - Pre-sale: 35% - Listing on exchanges: 20% - Treasury: 5% Investment Considerations AI Trump Coin represents an innovative approach by combining AI and cryptocurrency. However, potential investors are advised to conduct thorough research and consider the inherent risks associated with cryptocurrency investments. AI Trump Coin is a distinct project and should not be confused with Trump Coin ($TRUMP). Join the Community For those interested in learning more about AI Trump Coin and staying updated on its progress, the project encourages engagement through its community channels on X and Telegram. Social Links X: https://x.com/TrumpCoinAIcom Telegram: https://t.me/aitrumpcoincom Media Contact Brand: AI Trump Coin Contact: Media team Email: team@aitrumpcoin.com Website: http://aitrumpcoin.com

SHENZHEN, CHINA – January 08, 2025 – (ACN Newswire) – China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group” or “CMS”) is pleased to announce that on 8 January 2025, the Group through a wholly-owned subsidiary of the Company entered into a License, Collaboration and Distribution Agreement (the “Agreement”) with Alpha Cognition Inc. (“Alpha”) of the improved new drug ZUNVEYL（benzgalantamine delayed-release tablets）(“ZUNVEY” or the “Product”) for the treatment of mild-to-moderate dementia of the Alzheimer’s type. The Group is entitled to an exclusive right to develop, register, manufacture, import, export and commercialize the Product in Asia (excluding Japan), Australia and New Zealand (the “Territory”), Alpha reserves the right to manufacture and supply in the Territory. The term of cooperation commences on the effective date of the Agreement and extends for twenty years, which may be automatically renewed every five years upon the expiration unless terminated by notice from either party. As the second oral therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer’s disease during the past decade, ZUNVEYL demonstrates a potentially better safety profile to improve compliance of patients and therefore brings clinical benefits. CMS has rooted in the central nervous system therapeutic fields for years, continuously deploying and developing global differentiated and innovative products to strengthen its competitiveness in its advantageous specialty therapeutic fields. ZUNVEYL will further diversify our Group’s innovative drug product matrix and synergize with various central nervous system products including the marketed innovative drug VALTOCO (diazepam nasal spray), the original branded drug Deanxit (flupentixol and melitracen tablets) and the innovative pipeline drug Y-3 injection (a novel brain cytoprotectant that treats stroke). Leveraging its proven clinical development capability and compliant commercialization system with high efficiency, CMS will promote the approval of ZUNVEYL in China as soon as possible to bring a new drug option for the treatment of cognitive impairment in Alzheimer’s disease patients. About ZUNVEYL ZUNVEYL was approved in July 2024 by the U.S. FDA. As a new generation of acetylcholinesterase inhibitor (AChEI), ZUNVEYL can inhibit the acetylcholinesterase from breaking down the neurotransmitter acetylcholine, increase the level of acetylcholine in the central nervous system, and therefore alleviate cognition and memory impairment in Alzheimer’s disease patients. As a prodrug of galantamine, ZUNVEYL remains inert as it passes through the stomach and the intestine, and eventually releases the active drug into the bloodstream after being metabolized by the liver. With such a mechanism of action, ZUNVEYL is expected to have equivalent efficacy as galantamine with the potential of reducing gastrointestinal (GI) side effects and addressing certain tolerability issues. Galantamine has accumulated extensive evidence of efficacy and demonstrated long-term clinical benefit in the treatment of mild-to-moderate dementia of the Alzheimer’s type since the approval of FDA in 2001[1]. Moreover, GI adverse events documented across all studies for ZUNVEYL were less than 2% and no insomnia was observed[2]. Patent in regard to use of ZUNVEYL has already been granted in China. About Alzheimer’s disease Alzheimer’s disease is a chronic, progressive neurodegenerative disease characterized by progressive decline in memory and other cognitive functions, among which some of the patients will progress to dementia. Dementia is a kind of syndrome with acquired cognitive function impairment as the core symptom, and can lead to the reduction of patients’ daily living, learning, working and social interaction ability. Alzheimer dementia accounts for 50% to 70% of all types of dementia[3,4]. According to the epidemiological study results published in the Lancet Public Health[5], there are about 9.83 million patients with Alzheimer dementia in China, of which 7.93 million are mild-to-moderate[6]. With the intensifying aging trend, the number of patients and the consequent disease burden will further increase in the future. Currently the clinical treatment of Alzheimer’s disease can be categorized as improving cognitive symptoms and decelerating disease progression[7], and AChEI belongs to the former. According to the Research Report on the Diagnosis and Treatment of Alzheimer’s disease Patients in China[8], the high incidence of side effects is one of the major pain points for existing drugs for Alzheimer’s disease, suggesting that Alzheimer’s disease patients still have an urgent need for safer therapies. About ALPHA Alpha is a commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease and cognitive impairment with mild Traumatic Brain Injury. On July 2024, Alpha received approval by the FDA of its New Drug Application (NDA) for ZUNVEYL for the treatment of mild-to-moderate Alzheimer’s disease. Alpha will now focus on the development of commercial manufacturing and commercial sales of ZUNVEYL oral tablet formulation. Additionally, Alpha has three pre-clinical development programs: ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer’s disease, ALPHA-1062 sublingual formulation for the treatment of mild-to-moderate Alzheimer’s disease, ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild Traumatic Brain Injury. For more information about Alpha and its pipeline, please visit: https://www.alphacognition.com/ . About CMS CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs. CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients. CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development of its advantageous specialty fields and expand business boundaries. While strengthening the competitiveness of the cardio-cerebrovascular/gastroenterology business, CMS independently operates its dermatology and medical aesthetics business, and ophthalmology business, aiming to gain leading positions in specialty therapeutic fields, whilst enhancing the scale and efficiency. At the same time, CMS has expanded its business territory to the Southeast Asian market, striving to become a “bridgehead” for global pharmaceutical companies to enter the Southeast Asian market, further escorting the sustainable and healthy development of the Group. Reference: Xu, Hong et al. Long-term Effects of Cholinesterase Inhibitors on Cognitive Decline and Mortality. Neurology vol. 96,17 (2021): e2220-e2230. doi:10.1212/WNL.0000000000011832 Safety profile of ZUNVEYL as disclosed by Alpha: https://www.alphacognition.com/investors/news/alpha-cognitions-oral-therapy-zunveyl-receives-fda-approval-to-treat-alzheimers-disease- 2018 Chinese Guidelines for the Diagnosis and Treatment of Dementia and Cognitive Impairment (Chapter 1): Dementia Classification and Diagnostic Criteria [J]. National Medical Journal of China, 2018, 98 (13): 965-970. DOI: 10.3760/cma.j.issn.0376-2491.2018.13.003 2018 Chinese Guidelines for the Diagnosis and Treatment of Dementia and Cognitive Impairment (Chapter 2): Guidelines For Diagnosis and Treatment of Alzheimer’s Disease [J]. National Medical Journal of China, 2018,98 (13): 971-977. DOI: 10.3760/cma.j.issn.0376-2491.2018.13.004 Jia, Longfei et al. Prevalence, risk factors, and management of dementia and mild cognitive impairment in adults aged 60 years or older in China: a cross-sectional study. The Lancet. Public health vol. 5,12 (2020): e661-e671. doi:10.1016/S2468-2667(20)30185-7 Yuan, Jing et al. Severity Distribution of Alzheimer’s Disease Dementia and Mild Cognitive Impairment in the Framingham Heart Study. 1 Jan. 2021: 807-817. Mayo Clinic. 2024. Alzheimer’s Disease: Therapies to Improve Cognitive Symptoms and Decelerate Disease Progression. https://www.mayoclinic.org/zh-hans/diseases-conditions/alzheimers-disease/in-depth/alzheimers/art-20048103 Research Report on the Diagnosis and Treatment of AD Patients in China (2020). Alzheimer’s Disease Chinese (ADC). https://www.adc.org.cn/index.php/book/chinaadzlxzbg2020/chinaadzlxzbg2020-381.html CMS Disclaimer and Forward-Looking Statements This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert. This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections. Media Contact Brand: China Medical System Holdings Ltd. Contact: CMS Investor Relations Email: ir@cms.net.cn Website: https://web.cms.net.cn/en/home/ Source: China Medical System Holdings Ltd.

Taipei - January 07, 2025 - (SeaPRwire) - 为进一步简化台湾旅客前往菲律宾的签证程序，知名签证服务机构OntrailVisa宣布推出针对台湾居民的菲律宾eTravel电子入境卡申请服务。这项服务通过优化的流程设计和多语言支持，为台湾护照持有人提供无缝的在线体验。 菲律宾eTravel电子入境卡的重要性 根据菲律宾官方规定，所有旅客在进入和离开菲律宾之前，均需完成菲律宾eTravel电子入境卡的注册。此数字平台旨在收集旅客的基本信息，以加速边境通关流程。 然而，对于不熟悉英文或流程的台湾旅客而言，注册过程可能充满挑战。OntrailVisa顺应需求，开发了一套专为台湾居民设计的申请服务，为用户提供翻译为繁体中文的表格、全面的申请指导以及全天候客户支持，帮助旅客轻松完成注册并享受无忧出行体验。 服务亮点：为什么选择OntrailVisa？ 易于理解的中文支持 OntrailVisa特别将菲律宾eTA申请表格翻译成繁体中文，帮助台湾旅客克服语言障碍，轻松完成填写。同时，直观的用户界面和简化的表格设计，也大幅降低了填写错误的风险。 专业协助贯穿全程 申请过程中，OntrailVisa团队会提供实时提示，指导用户正确提交所需信息，显著降低被拒风险。遇到任何疑问，用户可随时联系24小时在线的客户支持团队。 高效处理时间 OntrailVisa承诺在收到完整材料后，1至2天内处理完毕并提交申请，为急需出行的旅客节省时间。此外，服务还提供全额退款保证，若申请被拒，用户仅需联系平台即可获得退款。 用户体验第一的全面优化 从自动验证功能到专家审核流程，OntrailVisa的技术和人工支持相辅相成，确保每位旅客的申请准确无误，避免因疏忽造成的错误或延误。 旅客的真实体验：轻松申请无后顾之忧 为了验证服务效果，OntrailVisa采访了多位使用平台申请菲律宾eTravel的旅客，其中包括台湾居民庄先生（Mr. Zhuang）。他表示：“我原本担心申请过程会很复杂，但OntrailVisa让这一切变得简单。尤其是中文支持，让我填写表格时完全没有压力。我很高兴选择了这个平台。” 庄先生的经历仅是众多用户满意评价中的一个例子，体现了OntrailVisa在提供卓越服务上的专业能力。 关于OntrailVisa OntrailVisa是一家专为台湾护照持有人提供旅行签证解决方案的机构，致力于为旅客简化复杂的申请流程。无论是申请前往菲律宾、美国还是越南的签证，OntrailVisa都能提供精准指导和全方位支持。 此外，OntrailVisa还通过其官方网站 提供详细的签证要求和申请指南，方便用户随时了解最新信息。 作为一家以客户为中心的企业，OntrailVisa的使命是通过可靠的信息、先进的技术和专业的团队支持，帮助旅客在繁忙的行程安排中节省时间、避免压力。 规划您的菲律宾之旅，从OntrailVisa开始 菲律宾作为台湾旅客热门的旅行目的地，以其丰富的自然景观和多样的文化吸引着无数游客。如今，通过OntrailVisa的菲律宾eTravel服务，旅客们可以更专注于计划行程，无需为复杂的签证手续而担忧。 访问OntrailVisa官网了解更多详情，让您的旅行计划轻松启程。 OntrailVisa，旅行无忧的最佳选择。 媒体联络 电子邮件：info@ontrailvisa.tw 官网：https://www.ontrailvisa.tw/philippines

Brasília, Brazil – January 07, 2025 – (SeaPRwire) – Kess Energy, a leading junior lithium miner based in Brasília, Brazil is proud to announce the launch of a ground-breaking organization, “Comunidades Avança Brasil” or Communities Forward Brazil (CFB), aimed at ensuring that the economic and social benefits of Brazil’s flourishing lithium mining boom are rapidly and equitably shared with local communities impacted by disruptive operations. The Brazilian lithium sector is experiencing an unprecedented expansion, driven by surging global demand for renewable energy solutions and electric vehicle technologies. While the industry has brought significant economic opportunities, there remains an urgent need to translate these gains into tangible improvements in the lives of communities living near mining sites. “Mining is a transformative force in our economy, but its true success lies in its ability to uplift the people and communities most affected by our activities,” said Inato Ramirez, Chairman of Kess Energy. “Through Communities Forward Brazil, we aim to work collaboratively with industry peers, local governments, and NGOs to create actionable solutions that address local needs—from infrastructure and education to health and environmental conservation.” Communities Forward Brazil’s key objectives include: Community engagement: Establishing open dialogue forums to listen to the concerns and aspirations of local residents. Fair redistribution of benefits: Advocating for policies that ensure a greater share of mining revenues is reinvested in local community projects. Sustainability and innovation: Partnering with stakeholders to implement environmentally sustainable practices that balance development with ecological preservation. Transparency and accountability: Promoting ethical business practices and transparent communication regarding mining activities and their impact. Kess Energy invites other mining industry players to join Communities Forward Brazil in creating a unified platform to champion sustainable development and community empowerment. “By joining forces, I think it’s possible that we can redefine the narrative of mining in Brazil,” added Mr. Ramirez. “Our goal is to ensure the legacy of the lithium boom is not only wealth creation for big business and shareholders but also the elevation of the communities who are the heart and soul of our nation.” About Kess Energy Kess Energy is a junior lithium mining company dedicated to meeting the increasing global demand for lithium through responsible and sustainable mining practices that respect and consider the needs of the communities in which its assets are located. With a portfolio of high-quality lithium assets and a commitment to innovation, Kess Energy is well-positioned to play a pivotal role in the energy transition while enabling communities to share in the commercial benefits of its business. Please contact +55 61 4042 9257 or visit our office at Centro Empresarial Varig, SCN QUADRA 04 BL B – Asa Norte, Brasília – DF, 70714-900, Brazil. Media Contact Brand: Kess Energy Contact: Joseph Hera Email: contact@kessenergy.com Website: https://kessenergy.com